Data gathered: November 16
AI Stock Analysis - Amarin (AMRN)
Analysis generated October 29, 2024. Powered by Chat GPT.
Amarin Corporation plc (NASDAQ: AMRN) is a biopharmaceutical company known for its flagship product, Vascepa (icosapent ethyl), which is derived from fish oil and used to lower triglycerides in adults with severe hypertriglyceridemia. The company focuses primarily on improving cardiovascular health and advancing the management of cardiovascular disease. Headquartered in Dublin, Ireland, Amarin's mission is to leverage drug research and technology to reduce the burden of cardiovascular disease globally.
Stock Alerts - Amarin (AMRN)
 |
Amarin | November 14 Price is down by -5.2% in the last 24h. |
|
Amarin | November 13 Price is up by 5% in the last 24h. |
|
Amarin | November 6 Price is down by -6% in the last 24h. |
|
Amarin | November 4 Price is up by 5.8% in the last 24h. |
Alternative Data for Amarin
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | 58 | Sign up | Sign up | Sign up |
| Patents | 129 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 47 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 30,857 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,218 | Sign up | Sign up | Sign up |
| Twitter Mentions | 19 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 31 | Sign up | Sign up | Sign up |
| Business Outlook | 25 | Sign up | Sign up | Sign up |
| Linkedin Employees | 449 | Sign up | Sign up | Sign up |
About Amarin
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
| Price | $0.50 |
| Target Price | Sign up |
| Volume | 2,010,000 |
| Market Cap | $214M |
| Year Range | $0.5 - $1.07 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
Amarin Corporation plc - Investigators to Present New REDUCE-IT Subanalysis of VASCEPA, VAZKEPA in Patients with and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic AcidNovember 11 - Finnhub |
|
 |
Amarin Corp PLC (AMRN) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines Amid ...October 31 - Yahoo |
 |
Amarin's Q3 Earnings In Line, Revenues Fall Shy of EstimatesOctober 30 - Yahoo |
 |
Amarin Plc (AMRN) Q3 2024 Earnings Call TranscriptOctober 30 - Yahoo |
 |
Amarin Corporation plc (AMRN) Q3 2024 Earnings Call TranscriptOctober 30 - SeekingAlpha |
|
Amarin Corporation plc 2024 Q3 - Results - Earnings Call PresentationOctober 30 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 43M | 63M | 16M | -25M | -24M | -0.060 |
| Q2 '24 | 68M | 63M | 43M | 1.5M | 210,000 | 0.004 |
| Q1 '24 | 57M | 65M | 32M | -10M | -13M | -0.020 |
| Q4 '23 | 72M | 74M | 45M | -5.8M | -4.1M | -0.010 |
| Q3 '23 | 66M | 70M | 30M | -19M | -21M | -0.050 |
Insider Transactions View All
| Berg Aaron filed to buy 805,380 shares at $0.6. August 5 '24 |
| Holt Patrick filed to buy 314,426 shares at $1.1. January 24 '24 |
| Ketchum Steven B filed to sell 566,100 shares at $0.8. December 14 '23 |
| Holt Patrick filed to buy 958 shares at $1. August 16 '23 |
| Holt Patrick filed to buy 206,933 shares at $1.1. August 16 '23 |
Similar companies
Read more about Amarin (AMRN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Amarin?
The Market Cap of Amarin is $214M.
What is the current stock price of Amarin?
Currently, the price of one share of Amarin stock is $0.50.
How can I analyze the AMRN stock price chart for investment decisions?
The AMRN stock price chart above provides a comprehensive visual representation of Amarin's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Amarin shares. Our platform offers an up-to-date AMRN stock price chart, along with technical data analysis and alternative data insights.
Does AMRN offer dividends to its shareholders?
As of our latest update, Amarin (AMRN) does not offer dividends to its shareholders. Investors interested in Amarin should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Amarin?
Some of the similar stocks of Amarin are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.